Federal Court Orders Preliminary Injunction on U.S. Sales of Medtronic's Infringing Transcatheter Valve

Federal Court Orders Preliminary Injunction on U.S. Sales of Medtronic's 
Infringing Transcatheter Valve 
IRVINE, CA -- (Marketwired) -- 04/11/14 --   Edwards Lifesciences
Corporation (NYSE: EW), the global leader in the science of heart
valves and hemodynamic monitoring, announced that the U.S. District
Court for the District of Delaware today granted a preliminary
injunction limiting the sale of Medtronic's CoreValve system in the
United States. The court ordered the injunction to go into effect in
seven business days. Today's hearing related to a federal jury
decision in 2010 that CoreValve willfully infringes Edwards' U.S.
Andersen transcatheter aortic valve replacement patent.  
At the conclusion of the hearing, Chief Judge Gregory Sleet ordered
Edwards and Medtronic to confer on what instances the CoreValve
device could continue to be used in the treatment of U.S. patients at
centers currently trained on CoreValve. There is a large body of
evidence demonstrating the safety and performance of the Edwards
SAPIEN valves, and the company remains committed to ensuring patients
have appropriate access to transcatheter therapy. 
Background
 This
case was initiated by Edwards in 2008. On April 1, 2010, a federal
jury found Medtronic willfully infringed Edwards' U.S. Andersen
patent and awarded damages. In Nov. 2012, the U.S. Court of Appeals
for the Federal Circuit affirmed the jury decision; in Oct. 2013, the
U.S. Supreme Court declined to hear Medtronic's appeal. 
The patent involved in this suit is part of the Andersen family of
patents. The U.S. Andersen patent was issued in 1995. A petition has
been filed with the U.S. Patent and Trademark Office to extend this
patent into early 2016. 
In a separate case, a federal jury in January found that Medtronic
CoreValve had willfully infringed Edwards' U.S. Cribier transcatheter
heart valve patent, and awarded damages to Edwards in that trial. 
About Edwards Lifesciences
 Edwards Lifesciences is the global leader
in the science of heart valves and hemodynamic monitoring. Driven by
a passion to help patients, the company partners with clinicians to
develop innovative technologies in the areas of structural heart
disease and critical care monitoring, enabling them to save and
enhance lives. Additional company information can be found at
www.edwards.com.  
Edwards, Edwards Lifesciences, the stylized E logo and SAPIEN are
trademarks of Edwards Lifesciences Corporation. All other trademarks
are the property of their respective owners. 
Media Contact:
Sarah Huoh
949-250-5070 
Investor Contact:
David K. Erickson
949-250-6826 
 
 
Press spacebar to pause and continue. Press esc to stop.